ArticleCurrent treatment options in psychiatry2020
Buprenorphine dosing for the treatment of opioid use disorder through pregnancy and postpartum.
Article in Current treatment options in psychiatry, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Adolescent prefrontal and amygdala molecular signatures of perinatal morphine versus buprenorphine exposure in mice.Neurotoxicology · 2026Article
- Interventions for opioid use disorder during the first year postpartum: A systematic review.Pregnancy (Hoboken, N.J.) · 2026Article
- From morphine to buprenorphine - Modeling opioid use disorder and its treatment during pregnancy: Effects on maternal care and offspring neurodevelopment in a translational rodent model.Pharmacology, biochemistry, and behavior · 2025Article
- Monthly buprenorphine depot injection (SUBLOCADE®) for opioid use disorder during pregnancy.The American journal on addictions · 2025Article
- Buprenorphine maintenance treatment and its outcome among opioid dependent pregnant women: A case series from India.Indian journal of psychiatry · 2025Article
- Gestational Opioid Exposure: From Morphine to MOUD - How Opioids Impact Offspring Development and Maternal Care.Current topics in behavioral neurosciences · 2025Review
- The effects of buprenorphine and morphine during pregnancy: Impact of exposure length on maternal brain, behavior, and offspring neurodevelopment.Neuropharmacology · 2024Article
- Commentary on Schmidt et al.: Informed patient preference and prioritizing access to medications for opioid use disorder for pregnant individuals.Addiction (Abingdon, England) · 2024Article
- Fetal and Infant Effects of Maternal Opioid Use during Pregnancy: A Literature Review including Clinical, Toxicological, Pharmacogenomic, and Epigenetic Aspects for Forensic Evaluation.Children (Basel, Switzerland) · 2024Review
- Perinatal morphine but not buprenorphine affects gestational and offspring neurobehavioral outcomes in mice.Neurotoxicology · 2023Article
- Interaction between buprenorphine and norbuprenorphine in neonatal opioid withdrawal syndrome.Drug and alcohol dependence · 2023Article
- Article
- Association Between Buprenorphine Dose and the Urine "Norbuprenorphine" to "Creatinine" Ratio: Revised.Substance abuse : research and treatment · 2023Article
- Incarceration status at buprenorphine initiation and OUD treatment outcomes during pregnancy.Frontiers in psychiatry · 2023Article
- Addiction treatment in the postpartum period: an opportunity for evidence-based personalized medicine.International review of psychiatry (Abingdon, England) · 2021Review
- A Pharmacologic Evaluation of Buprenorphine in Pregnancy and the Postpartum Period.Journal of addiction medicineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
purpose of reviewOpioid-related deaths are a leading cause of mortality during pregnancy through 12 months postpartum. Buprenorphine use during pregnancy is increasing, yet expert opinion on its dosing through the perinatal period is limited. We provide a review of the current clinical literature on buprenorphine dosing during pregnancy through 12 months postpartum. and present data from a retrospective chart review of patients at our institution describing trends in buprenorphine dosing during pregnancy and postpartum. Utilizing this information, we synthesize findings to provide clinical recommendations for providers. RECENT
findingsExisting literature during pregnancy reflects how many women increase and split total daily buprenorphine doses as gestational age advances. SUMMARY: We present data from a retrospective chart review of patients at our institution describing trends in buprenorphine dosing during pregnancy and postpartum. Utilizing this information, we synthesize findings to provide clinical recommendations for providers. Changes in the total daily dose of buprenorphine used across pregnancy and through 12 months postpartum at the individual level do not follow consistent patterns, highlighting substantial individual variability. Altogether, buprenorphine dosing should be individualized through pregnancy and postpartum with frequent evaluations by providers and solicited input from patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.